Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB
Ratings Surperformance© - Kobayashi Pharmaceutical Co., Ltd.

Ratings ESG MSCI

Ratings ESG MSCI - Kobayashi Pharmaceutical Co., Ltd.

Ratings Kobayashi Pharmaceutical Co., Ltd.: Strengths and Weaknesses

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Kobayashi Pharmaceutical Co., Ltd.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses: Kobayashi Pharmaceutical Co., Ltd.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company sustains low margins.
  • With an expected P/E ratio at 51.04 and 39.44 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Rating Financials

Kobayashi Pharmaceutical Co., Ltd. SectorGermany

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings
Fundamental Rankings - Kobayashi Pharmaceutical Co., Ltd.

Rating Valuation

Kobayashi Pharmaceutical Co., Ltd. SectorGermany

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings
Fundamental Rankings - Kobayashi Pharmaceutical Co., Ltd.

Rating Consensus

Kobayashi Pharmaceutical Co., Ltd. SectorGermany

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

-

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings
Fundamental Rankings - Kobayashi Pharmaceutical Co., Ltd.

Rating Business Predictability

Kobayashi Pharmaceutical Co., Ltd. SectorGermany

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Fundamental Rankings - Kobayashi Pharmaceutical Co., Ltd.

Rating Revisions

Kobayashi Pharmaceutical Co., Ltd. SectorGermany

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings
Fundamental Rankings - Kobayashi Pharmaceutical Co., Ltd.


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.31B
BBB
345B
AA
224B
AA
131B
AAA
69.55B
AAA
46.19B
AA
- -
45.29B
AA
33.79B
A
33.78B
A
32.18B
AAA
Average 96.35B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. 4967 Stock
  4. KOY Stock
  5. Ratings Kobayashi Pharmaceutical Co., Ltd.